Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | LIPE | Q05469 | 3/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22815763 | 0.87 | NOTUM (0.48) | LIPEKCNH2ABL1FFAR4CHRM4 | |
| SCHEMBL14636981 | 0.84 | ABL1 (0.47) | KCNA5LIPEABL1NOTUMEPHX2 | |
| SCHEMBL1244796 | 0.83 | FFAR4 (0.50) | KCNA5SLC6A4LIPESLC6A3FFAR4 | |
| SCHEMBL22042168 | 0.81 | EPHX2 (0.48) | ABL1CACNA1BCHRM4EPHX2 | |
| SCHEMBL1471204 | 0.79 | PPARD (0.42) | KCNA5LIPECCR6KCNH2PPARD | |
| SCHEMBL1471203 | 0.79 | PPARD (0.42) | KCNA5LIPECCR6KCNH2PPARD | |
| SCHEMBL25390074 | 0.78 | BPTF (0.54) | KCNA5SLC6A4LIPECACNA1B | |
| SCHEMBL13858855 | 0.78 | BPTF (0.54) | KCNA5SLC6A4LIPECACNA1B | |
| SCHEMBL19733783 | 0.78 | CASR (0.46) | KCNA5LIPECCR6KCNH2PPARD | |
| SCHEMBL1471142 | 0.78 | POLB (0.42) | KCNA5LIPECCR6KCNH2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308169-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308169-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS | SQOR, NQO1, NDUFS3 | KCNA5 3118/4885SLC6A4 4044/4885LIPE 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.